Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

2 Beaten-Down Stocks to Avoid

TheMotleyFool 
0 0 27.06.25
2 Beaten-Down Stocks to Avoid: https://g.foolcdn.com/editorial/images/822744/scientist-altering-dna-genome-project.jpg
 

Over the past year, Editas Medicine (NASDAQ: EDIT) and Sarepta Therapeutics (NASDAQ: SRPT), two biotech companies, have encountered severe headwinds that aren't at all related to broader market volatility. Both drugmakers have seen their shares plummet over the trailing-12-month period. However, while investors are supposed to buy low, even at current levels, Editas Medicine and Sarepta aren't attractive stocks to buy.

Let's consider why investors should stay a safe distance away from these two biotech companies.

Image source: Getty Images.

Continue reading


Source Fool.com

Sarepta Therapeutics Stock

€14.81
0.070%
There is nearly no change for the Sarepta Therapeutics stock today. Compared to yesterday it only changed by €0.010.
Currently there is a rather positive sentiment for Sarepta Therapeutics with 4 Buy predictions and 0 Sell predictions.
Based on the current price of 14.81 € the target price of 135 € shows a potential of 811.85% for Sarepta Therapeutics which would more than double the current price.
Show more
Like: 0
EDIT
Share

Comments

Not a member yet? Sign up for free!